Approval Background

Olaparib is a poly(ADP‑ribose) polymerase (PARP) inhibitor that blocks DNA damage repair mechanisms in tumor cells. In the Phase 3 SOLO1 trial, progression‑free survival in BRCA‑mutated ovarian cancer patients was markedly improved. This efficacy and safety data drove EMA approval.

Positioning Compared to Competing Drugs

Compared with other PARP inhibitors such as rucaparib, olaparib demonstrates higher response rates in the BRCA‑mutated patient cohort, and when used as maintenance therapy, it provides sustained disease control. This represents a key differentiator that expands therapeutic options in clinical practice.

Reimbursement and Market Entry Barriers

Health authorities across Europe require price negotiations and cost‑effectiveness analyses. The initial price is high, which may delay reimbursement approval, and some countries may limit approved indications. These procedures moderate market penetration speed but ultimately create opportunities to broaden patient access over the long term.

Market Size and Long‑Term Outlook

EMA approval opens the door to the European oncology market valued at approximately €100 billion. Since BRCA‑mutated ovarian and breast cancer patients represent about 5–6% of the total, continued clinical expansion will be the primary driver of revenue growth. If the label expands to additional indications, the market opportunity is expected to increase further.